First ACCE Review: Population-based Prenatal Screening for Cystic Fibrosis via Carrier Testing
This website is archived for historical purposes and is no longer being maintained or updated.
“Population-based Prenatal Screening for Cystic Fibrosis via Carrier Testing” is the first systematic review using the ACCE model process, with additional reviews under development. The purpose of these reviews is to provide a comprehensive compilation of information and is intended for use by individuals and groups involved with shaping policy. The document is not, in and of itself, intended to recommend policy.
- Introduction[PDF 386 KB]
A description of the model process and overview (Genetic Test Brief)
- Disorder/Setting[PDF 98 KB]
What is the test aimed at identifying and how will it be used?
- Analytic validity[PDF 649 KB]
How well does the test perform in the laboratory?
- Clinical validity[PDF 1.7 MB]
How well does the test perform in the clinical setting?
- Clinical utility[PDF 1 MB]
How useful is the test?
- ELSI[PDF 75 KB]
What are the ethical, legal and social implications associated with testing?
- Glossary[PDF 239 KB]
Terms used in the report
- Page last reviewed: December 28, 2010 (archived document)
- Content source: